Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | FAAH | O00519 | 8/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5267961 | 0.89 | RPA1 (0.39) | KMT2APTK2B | |
| SCHEMBL5269108 | 0.88 | CA9 (0.43) | CA9FAAHCHRNA7MKNK2JMJD6 | |
| SCHEMBL5523473 | 0.88 | FAAH (0.35) | FAAHPTK2B | |
| SCHEMBL5526891 | 0.87 | PTK2B (0.33) | PTK2B | |
| SCHEMBL4931448 | 0.86 | KMT2A (0.46) | CA9FAAHMGLLPOLBTP53 | |
| SCHEMBL5266524 | 0.83 | CA9 (0.44) | CA9FAAHCHRNA7JMJD6MGLL | |
| SCHEMBL5268263 | 0.83 | MGLL (0.40) | MGLLTP53 | |
| SCHEMBL5267493 | 0.82 | PTGS2 (0.43) | MGLLMAPTKMT2A | |
| SCHEMBL5265523 | 0.82 | CFTR (0.39) | MGLL | |
| SCHEMBL5268146 | 0.82 | HPGD (0.39) | CHRNA7MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254881-A1 | Pyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| US-20070219210-A1 | Amidopyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| EP-1785418-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-05-16 | — | — | EP | disclosed |
| EP-1698626-A1 | AMIDOPYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254881-A1 | Pyrazole Derivative | PTGER1, PTGS1, PTGER2 | CA9 3231/4885FAAH 1657/4885CHRNA7 4207/4885 |
| US-20070219210-A1 | Amidopyrazole Derivative | PTGER1, PTGS1, PTGER2 | CA9 3499/4885FAAH 63/4885CHRNA7 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.